Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27688414 | 0.84 | L3MBTL3 (0.88) | HPGDALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL2638071 | 0.84 | HPGD (0.86) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL1587750 | 0.82 | HPGD (0.58) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL5721732 | 0.81 | HPGD (0.67) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL3254670 | 0.81 | HPGD (0.62) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL2637800 | 0.80 | HRH3 (0.60) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL4157157 | 0.79 | HPGD (0.66) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL30340462 | 0.79 | HPGD (0.64) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL3184163 | 0.79 | HPGD (1.00) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL1587143 | 0.79 | HPGD (0.58) | HPGDALDH1A1POLBL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968542-B2 | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-28 | — | — | US | claimed |
| US-7968542-B2 | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1904472-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007010954-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | HPGD 2277/4885ALDH1A1 2481/4885POLB 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.